|
Phase 2 study of ET-743 in subjects with advanced ovarian cancer Clinical Trials Facts presented on Clinical Trials Search is not designed to be a substitute for certified medical advice, travels to or treatment with a real dr.. We aren't doctors. Always consult your mD on Phase 2 study of ET-743 in subjects with advanced ovarian cancer conditions. Clinical Trials Search.org is a website dedicated to listing clinical research studies in human subjects. Phase 2 study of ET-743 in subjects with advanced ovarian cancer Clinical research trials and Phase 2 study of ET-743 in subjects with advanced ovarian cancer medical trials occur in many of places across the U.S.A.. A clinical trial or clinical study is a research project with human volunteer subjects. Clinical drug trials and pharmaceutical clinical trials generally assess the effectiveness of new does drugs. The role of the studies / undertakings is to figure out certain human healthcare questions. Clinical trials are a popular means for doctors, government agencies, and private sector corporations to locate treatments for all forms of circumstances, including Phase 2 study of ET-743 in subjects with advanced ovarian cancer. Phase 2 study of ET-743 in subjects with advanced ovarian cancer Clinical Trials and other clinical trials permit volunteers to get medical treatment options before they are available to the masses. Most times the human subjects acquire treatment for free of charge, and sometimes they are paid for their time. Occasionally there is a cost for a Phase 2 study of ET-743 in subjects with advanced ovarian cancer clinical trial. Participants oftentimes recieve the finest healthcare available for their Phase 2 study of ET-743 in subjects with advanced ovarian cancer condition. Dangers are a reality, nonetheless, and might include extra or frequent physician calls, health hazards (potentially life-endangering), and/or the treatment being ineffectual. Trials are federally regulated with strict guidelines to protect clinical trials subjects.
|
|
|
|
|
|
|
Home > "P" Clinical Trials Conditions > Phase 2 study of ET-743 in subjects with advanced ovarian cancer  Phase 2 study of ET-743 in subjects with advanced ovarian cancer
Phase 2 study of ET-743 in subjects with advanced ovarian cancer
For Condition: Ovarian Cancer
Status: Recruiting
Sponsor(s): Johnson & Johnson Pharmaceutical Research and Development, L.L.C. , PharmaMar
Synopsis: This is a study to test the safety and effectiveness of an investigational chemotherapy agent in subjects with advanced ovarian cancer. After a subject meets all entry criteria and signs informed consent she will be enrolled in the study. Participants will be required to attend regular clinic visits to receive study medication and have their status monitored. They will also be required to have radiologic tumor assessments performed at multiple times throughout the study. A detailed explanation can be provided by the investigator conducting this study.
Details:
Eligibility:
Study Type: Interventional, Treatment
Minimum Age/Maximum Age: 18 Years/
Genders: Female
Protocol Entry Criteria: - Female subjects 18 years of age or older - Diagnosis of advanced epithelial ovarian cancer - Progression or recurrence during or after platinum containing regimen - At least one measureable tumor lesion - Adequate bone marrow, hepatic and renal function - Performance status ECOG 0 or 1
Total Enrollment:
Location and Contact Information:
Hematology Oncology Specialists *Recruiting*
New Orleans, Louisiana, 70115
United States
Recruiting Mary Ostroske 504-894-7115
Hematology Oncology, P.C. *Recruiting*
Stamford, Connecticut, 06902
United States
Recruiting Susan Murdock 203-323-8944
USC, Norris Comprehensive Cancer Center *Recruiting*
Los Angeles, California, 90089
United States
Recruiting Susan Edwards 323-865-0455
Dana Farber Cancer Institute / Mass General Hospital *Recruiting*
Boston, Massachusetts, 02114
United States
Recruiting Laura Sullivan 617-726-4638
Norton Hospitals, Inc., Louisville Oncology *Recruiting*
Louisville, Kentucky, 40202
United States
Recruiting Daniella Neamtu 502-629-4679
University of Oklahoma Health Science Center *Recruiting*
Oklahoma City, Oklahoma, 73104
United States
Recruiting Ingrid Block 405-271-8777
US Oncology, Dallas *No longer recruiting*
Dallas, Texas, 75204
United States
No longer recruiting
Additional Information:
Study ID Numbers: ET743-INT-11;
Study Start Date:
Record last reviewed: February 2004
Additional information available at: clinicaltrials.gov
Clinicaltrials.gov Reference link: NCT00050414
Other Ovarian Cancer Studies:
1. Breast Imaging Studies in Women at High Genetic Risk of Breast Cancer: Menstrual Cycle Study
2. Paclitaxel, Cisplatin, and Topotecan With or Without Filgrastim in Treating Patients With Newly Diagnosed Stage III or Stage IV Epithelial Ovarian Cancer
3. Safety and Efficacy of S-8184 in Second Line Treatment of Stage III or IV Ovarian Cancer
4. Gemzar (gemcitabine) and Alimta (pemetrexed) in the Treatment of Patients with Recurrent Platinum-Sensitive and Platinum-Resistant Ovarian or Peritoneal Cancer
5. Acupuncture to Improve Quality of Life in Patients With Advanced Cancer
Related Studies:
Other Ovarian Cancer Clinical Trials
Other Oklahoma Clinical Trials
Other Oklahoma City Clinical Trials
Phase 2 study of ET-743 in subjects with advanced ovarian cancer
|
|
|
|
|
|
|
|
